Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Related Articles

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Drug Des Devel Ther. 2017;11:893-900

Authors: Friend R, Bhutani M, Voorhees PM, Usmani SZ

Abstract
Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

PMID: 28356715 [PubMed - in process]

http://ift.tt/2ooDW3k